• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Answers Questions in Update of COVID-19 Clinical Trial Guidance

FDA Answers Questions in Update of COVID-19 Clinical Trial Guidance

April 20, 2020

Sponsors that choose to conduct remote trial monitoring during the COVID-19 crisis should focus on the most critical site documentation and source data and ensure the security of the data by creating a secure electronic viewing portal or using a sponsor-controlled electronic system or cloud-based repository, says an updated guidance the FDA released last week.

The expanded guidance adds several new question-and-answer segments to the agency’s March 18 guidance on conducting clinical trials during the COVID-19 crisis, including advising sites to use fax, email and phone communication to obtain informed consent from patients unable to travel to the trial site as long as the approach includes a method of ensuring the signer of the consent is actually the person who intends to enroll in the trial.

The FDA also says infusion of an investigational drug may be done by a local healthcare provider who is not involved in the trial as long as that person has the appropriate training and is supervised by a physician with experience in administering the class of the drug involved.

In the case of trials of drugs with FDA approval for other indications, the guidance says patients who are unable to receive the drug from the trial site may purchase the commercially available product with a prescription from a local physician. The FDA says it would not consider this practice a violation of regulations against sponsors charging trial participants for an investigational drug and “would not object” to the sponsor reimbursing the patient for the cost.

In the rare circumstance of computer systems being rendered inoperable or inaccessible by the pandemic, sponsors can apply to the FDA for a short-term waiver of electronic document submission requirements. Technical difficulties with electronic transmission, however, should be referred to the agency’s electronic submission staff, the guidance says.

Read the guidance here: https://bit.ly/3esTQE0.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing